All web articles
As first EU Ministerial meeting on tuberculosis closes, MSF calls on the EU to triple funding for TB R&D
As the first-ever Eastern Partnership Ministerial Conference on Tuberculosis and Multidrug-Resistant Tuberculosis concludes in Riga, Latvia today, Médecins Sans Frontières (MSF) calls on the European...
Decentralization key for scaling up MDR-TB treatment in Myanmar. Ko Thet Oo started treatment for multi-drug resistance tuberculosis (MDR-TB) about two months ago at the Médecins Sans Frontières...
Last updated 24 March 2015
Ready, set, slow down: New and promising DR-TB drugs are grabbing headlines but not reaching patients
The buzz started well before the first new TB drug in half a century was approved for use on the last day of 2012: two forthcoming new TB medicines would radically improve cure and survival rates...
20 March, 2015 – International organisations Partners In Health (PIH), Médecins Sans Frontières/Doctors Without Borders (MSF), Interactive Research and Development (IRD) and their financial partner...
New York, March 9, 2015 - As the Trans-Pacific Partnership Agreement (TPP) negotiations progress toward their anticipated conclusion, negotiators will meet in Hawaii this week, where intellectual property...
Last updated 11 March 2015
Central African Republic: MSF starts a vaccination campaign in the largest displaced persons' camp in the country
This week, Médecins Sans Frontières/Doctors Without Borders (MSF) starts a round of vaccinations for at least 18,000 children up to 15 years old, most of them living in the IDP camp in Batangafo,...
Last updated 26 February 2015
Preliminary Results of the JIKI Clinical Trial to test the Efficacy of Favipiravir in Reducing Mortality in Individuals Infected by Ebola Virus in Guinea
Preliminary data from the JIKI clinical trial, which is testing the efficacy of favipiravir in reducing mortality associated with Ebola, provide two important pieces of information:
Last updated 25 February 2015